Does fish oil help dry eye? The biggest trial found no edge over placebo

Ask an optometrist or the internet about dry, gritty eyes and omega-3 fish oil is one of the first suggestions you will hear. The recommendation is so common it can sound settled. It is not. When the question was put to a large, rigorously designed randomised trial, fish oil did no better than a placebo — and a systematic review of the wider literature leaves the case uncertain at best [s1][s2]. This is a textbook example of a plausible supplement whose reputation has outrun its evidence.

The trial built to settle it

The Dry Eye Assessment and Management (DREAM) study, funded by the United States National Eye Institute, is the strongest test to date [s1]. It enrolled patients with moderate-to-severe dry eye disease and randomly assigned them to a daily dose of 3,000 mg of fish-derived omega-3 fatty acids (EPA and DHA) or to an olive-oil placebo, following them for a year [s1]. In all, 349 patients were assigned to the supplement and 186 to placebo, with 329 and 170 respectively in the primary analysis [s1].

The main outcome was change in the Ocular Surface Disease Index, a 0-to-100 symptom score on which higher numbers mean worse symptoms. Both groups improved — and by almost the same amount. Symptom scores fell by 13.9 points with fish oil and 12.5 points with placebo, a difference of just 1.9 points that was not statistically significant (95% confidence interval −5.0 to 1.1; p=0.21) [s1]. The result held across the pre-specified subgroups [s1].

The objective signs told the same story. There were no meaningful differences between the groups in conjunctival staining (mean difference 0.0), corneal staining (0.1 point), tear break-up time (0.2 seconds) or Schirmer's test of tear production (0.0 mm) [s1]. This was not a case of a supplement failing because nobody took it: adherence, checked by measuring omega-3 levels in red blood cells, was 85.2% at 12 months, and side-effect rates were similar in both arms [s1]. People took the fish oil, and it simply did not outperform the placebo.

Why both groups got better

The near-identical improvement in both arms is the instructive part. Dry eye symptoms fluctuate, people enrolled in a trial tend to use their other treatments more diligently, and expectation alone lifts subjective scores — the same placebo dynamic that inflates apparent benefit for many over-the-counter remedies. A single-arm "before and after" study of fish oil would have shown a 13.9-point improvement and been hailed as proof; the randomised comparison reveals that almost all of it would have happened anyway — which is exactly why controlled trials, not testimonials, are what settle these questions [s1].

What the broader evidence adds

Supporters point out that DREAM is one trial, so the wider synthesis matters. A Cochrane review pooled 34 randomised trials involving 4,314 participants across 13 countries [s2]. Its verdict is hedged and modest. For long-chain omega-3 versus placebo, there may be little to no reduction in dry-eye symptoms (mean difference −2.47, 95% confidence interval −5.14 to 0.19, rated low-certainty evidence) [s2]. The reviewers found a probable small increase in tear production on the Schirmer test (mean difference 0.68 mm per five minutes, 95% confidence interval 0.26 to 1.09), but judged it not clinically meaningful [s2].

The review's authors concluded that omega-3 supplementation has a "possible" role in managing dry eye, but that the evidence is uncertain and inconsistent — and they flagged that over half the included studies had a high risk of bias in at least one domain [s2]. That is a long way from the confident recommendation the supplements attract.

The bottom line

The claim does not survive its best test. In the largest, best-funded trial, 3,000 mg of fish oil a day for a year did not relieve dry eye better than an olive-oil placebo, on either symptoms or the physical signs [s1]. The pooled evidence is weak and mixed, pointing at most to a small, uncertain effect [s2]. Omega-3 is generally safe and has other reasons people take it, but for dry eye specifically the honest summary is that it probably will not do much. Anyone with persistent eye discomfort is better served by an assessment of the cause than by a supplement; this is an informational summary, not medical advice.

Sources

• n−3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease — New England Journal of Medicine, 2018-04-13
• Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease — Cochrane Database of Systematic Reviews, 2019-12-18